The IGF-I axis in kidney and skeletal muscle of potassium deficient rats  by Hsu, Fay W. et al.
Kidney International, Vol. 52 (1997), pp. 363—3 70
The IGF-I axis in kidney and skeletal muscle of potassium
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FAY W. Hsu, TANNY TSAO, and RALPH RABKIN
Departments of Medicine, Stanford University and Veterans Affairs Medical Center, Palo Alto, California, USA
The IGF-I axis in kidney and skeletal muscle of potassium deficient
rats. Potassium deficiency in the rat results in growth retardation, muscle
wasting and renal hypertrophy. This study tests the thesis that K deficiency
leads to tissue distinct changes in the local IGF-I system and cell sensitivity
to IGF-I that favors renal enlargement on the one hand and impaired
muscle growth on the other. In rats after eight days of K deficiency,
compared to pair-fed control rats, food utilization and muscle and body wt
gain were attenuated while the kidneys enlarged. In muscle GH receptor
and IGF-I gene expression, IGF-I peptide and IGF binding protein-S
(IGFBP) levels were decreased. Together with reduced food utilization,
these changes may contribute to the attenuated muscle growth. In the
enlarged kidneys despite a fall in IGF-l mRNA level, IGF-I peptide
concentration was increased more than twofold. This increase in IGF-I
could be caused by the increase in kidney IGFBP-1 gene and protein
expression and the decrease in kidney IGF-I degrading activity noted in K
deficiency. Treatment with IGF-I failed to induce body or muscle growth,
but induced a further increase in kidney size and enlargement of the
spleen. Thus, in K deficiency the spontaneous increase in IGF-I levels in
the kidney that is IGF-I sensitive may well be a cause of the renal
hypertrophy.
Growth retardation, weight loss and muscle wasting are fea-
tures of potassium deficiency in the rat and are in part a
consequence of reduced food intake [1]. However, unlike the
renal atrophy that accompanies restricted food intake [2], K
depletion is followed by renal enlargement due to cellular hyper-
trophy and hyperplasia [3]. If the K deficient state is sustained,
then progressive tuhulointerstitial fibrosis invariably develops [41
and in humans there is an increased risk of renal cyst formation
[5]. Among the factors that have been implicated in the acceler-
ated renal growth, and paradoxically also in the retarded body and
muscle growth, is insulin-like growth factor-I (IGF-I) [6, 7]. This
is a potently anabolic growth factor that promotes longitudinal
body growth [8].
Insulin-like growth factor-I is produced in tissues throughout
the body, including kidney but the main source of circulating
IGF-I is liver [8]. The main regulators of IGF-I production are
growth hormone (GH) and nutrient intake [9, 10]. The action of
IGF-I is modulated by other components of the IGF-1 system and
these must be considered when studying this growth factor. These
components include the receptors for GH and IGF-I and the
insulin-like growth factor binding proteins (IGFBP). The binding
proteins have a high affinity for IGF-I and by complexing with
the growth factor affect its delivery to cells and modulate its
bioactivity [reviewed in 8]. Six different IGFBPs have been
identified and are found in varying amounts in tissues throughout
the body [11]. In the circulation 98 to 99% of the IGF-I is bound
to the IGFBPs [8, 12]. IGFBP-3 is the most abundant circulating
binding protein and usually -—90% of the plasma IGF-I circulates
complexed to both IGFBP-3 (molecular wt ——-40 to 50 kDa) and
an acid labile subunit (—85 kDa) to form a 150 kDa moiety. This
large size severely limits the transcapillary passage of IGF-I and
prolongs its half-life. A small amount of circulating IGF-I is
bound to IGFBP-1, -2, -4 and -6, forming smaller complexes that
escape more rapidly out of the circulation [13, 14].
Soon after restricting the intake of K, kidney IGF-I content
increases transiently returning to baseline within a week, and thus
it has been suggested that IGF-I may serve as an early promoter
of the exaggerated renal growth [7]. In contrast to the increase in
kidney IGF-I levels, serum IGF-I levels fall in young, rapidly
growing K-deficient rats, which may contribute to their reduced
body growth and muscle weight [1, 6]. Growth hormone secretion
is also attenuated, however; treatment with GH or IGF-I, despite
correcting the serum IGF-I levels, does not restore body or muscle
growth [15, 16]. Therefore, some mechanism other than IGF-I
deficiency must also be operative. We propose that K deficiency
leads to tissue distinct changes in the local IGF-I system and cell
sensitivity to IGF-I that favors continued renal enlargement on
the one hand and impaired muscle growth on the other. To this
end we studied rats eight days after being placed on a K deficient
diet compared to pair-fed normal controls. Some of the K
deficient and pair-fed control rats were treated with IGF-I so as to
evaluate the responsiveness of different tissues to the growth
promoting action of this peptide.
METHODS
Animal and experimental design
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Male Sprague-Dawley rats weighing —180 g were placed on a
1% K diet, and after a run-in period of five days they were divided
into four groups. Group 1 consisted of vehicle-treated control rats
maintained on the 1% K diet and pair fed with the Group 2 rats.
Group 2 consisted of vehicle-treated K deficient rats fed a 0.01%
K diet. This diet was identical to the 1% K diet in other respects
(Purina, Richmond, IN, USA). Group 3 consisted of IGF-I
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treated control rats maintained on the 1% K diet and pair fed with
the Group 4 rats. Group 4 consisted of IGF-I treated K deficient
rats maintained on an ad libitum 0.01% K diet. Vehicle (acetic
acid buffer) or IGF-I (240 jig/day) was delivered by 'seven day'
osmotic minipumps (Alza Corp., Palo Alto, CA, USA) that were
placed s.c. during light sodium methohexital anesthesia (50 mg/kg
i.p.). In addition vehicle or 100 jig IGF-I was given as a bolus s.c.
injection immediately after implanting the pumps. On the eighth
day of study IGF-I (300 jig) or vehicle was given s.c. in two divided
doses sixteen hours apart and the rats were sacrificed three hours
later. The kidney, liver, spleen, and gastrocnemius muscle were
removed, weighed, frozen in liquid nitrogen and stored at —80°C.
During the study rats were weighed daily and their food consump-
tion measured.
Northern blot analysis
Total RNA was isolated from tissues by an acid guanidinium
thiocyanate-phenol chloroform single step method and size-sep-
arated by formaldehyde agarose gel electrophoresis as previously
detailed [17]. In brief, formaldehyde treated samples containing
15 to 30 jig RNA, ethidium bromide and bromophenol blue were
loaded and electrophoresed on a denaturing agarose gel contain-
ing 0.55 M formaldehyde. RNA was transferred to nitrocellulose
filters and photographed under UV light. Filters were then
prehybridized in a solution containing 50% formamide, 1.5 X
SSPE, 2.5 X Denhart's solution, 50 jig salmon sperm DNA, 0.2%
SDS at 42°C for four hours. The mRNA levels of the GH
receptors, IGFBP-1, -2, -3, -4, and -5, were detected by hybridizing
radiolabeled cDNA probes to the mRNA at 42°C overnight.
Washed filters were then exposed to X-Ray films and the mRNA
quantitated by laser densitometry (GelscanXL; Pharmacia LKB,
Alameda, CA, USA). Alternatively the filters were exposed and
the signals measured in a Phosphorimager (Molecular Dynamics,
Sunnyvale, CA, USA). The abundance of each mRNA was
corrected for the 18S rRNA levels obtained from photographic
negatives of the nitrocellulose filters.
The cDNA probes for the five IGFBPs studied were prepared
from rat cDNAs (Dr. S. Shimasaki, Whittier Institute, La Jolla,
CA, USA). The IGFBP-1 probe consisted of 407 bp correspond-
ing to the coding region spanning nucleotide position 486 to 892
in the rat IGFBP-1 cDNA sequence. The IGFBP-2 probe com-
prised of 342 bp spanning nucleotide positions 670 to 1011. The
IGFBP-3 probe comprised 636 bp spanning nucleotide positions
196 to 831. The IGFBP-4 probe consisted of 354 bp spanning
nucleotide position 487 to 840. The IGFBP-5 probe comprised
259 bp spanning nucleotide position 856 to 1114. The GH
receptor probe was prepared from the 2.2 kb full length mouse
cDNA (Dr. F. Talmantes, University of California, Santa Cruz,
CA, USA). This eDNA encodes the extra- through intracellular
domain of the receptor [18]. The eDNA probes were labeled with
50 jiCi [32P]-dCTP by a random primer method (DNA labeling kit
70200; United States Biochemical Corporation, Cleveland, OH,
USA). Purification of the radiolabeled probes was achieved
through a G-50 Sephadex column.
Solution hybridization/RNAse protection assay
These assays were performed as previously detailed [17]. In
brief, total RNA was hybridized with alpha-32P-CTP labeled
antisense IGF-I or IGF-I receptor and 18S rRNA probes over-
night. The mixture was then incubated with an RNase digestion
buffer followed by the addition of proteinase K. Ethanol precip-
itated protected hybrids were separated on a 5% polyacrylamide/
8 M urea denaturing gel. Autoradiographs or phosphorimages
were obtained and the density of the protected bands were
measured. Only the Ea IGF-I mRNA transcripts were quantitated
since it accounted for > 95% of the IGF-1 mRNA signal in the
kidney and muscle. The IGF-I riboprobe, a 376 bp Sau3A-EcoRI
fragment, was designed to detect both the Ea and Eb IGF-I
mRNAs [19]. The IGF-I receptor riboprobe contained 280 bases
complementary to the IGF-I receptor mRNA. The 1 8S riboprobe
contained 80 complimentary bases of the human 18S rRNA [20].
Kidney plasma membrane IGF-I receptor binding assay
Crude plasma membranes were isolated from the kidney exactly as
previously described [17]. Tissues were homogenized in 8% buffered
sucrose, pH 7.0, followed by differential centrifugation and collection
of a 47,000 g pellet in calcium-free Krebs-Ringer Hepes buffer
(KRH, pH 7.4). Membrane receptor binding was measured, with
minor modification as before [17]. In brief 100 jig of membrane
protein was preincubated in 1 M MgCI2 for five minutes then washed
with KRH. Membranes were then incubated at 4°C overnight with
lOhl M '251-IGF-I in a binding buffer consisting of 150 mivi NaCl, 50
mM HEPES, pH 7.4 containing 0.1% BSA, 2 msi bacitracin and 5 mM
N-ethylmaleimide. Free and membrane-bound 1251-IGF-I were sep-
arated by centrifugation. The pellet was washed and the radioactivity
counted. Nonspecific 1251-IGF-I binding was determined by displace-
ment with 10_6 M of unlabeled IGF-I or des(1-3)IGF-I, an analog
with reduced IGFBP affinity. Similar results were obtained with both
peptides as before [17]. These peptides were gifts from Genentech
Inc. (South San Francisco, CA, USA). IGF-I was radiolabeled with
1251-Na [17].
Solubilized spleen and skeletal muscle IGF-I receptor binding
assay
A crude solubilized receptor preparation was made from frozen
spleen and a semipurified receptor preparation from gastrocne-
mius muscle [21]. The tissues were powdered in liquid nitrogen
and then homogenized and solubilized in buffer containing 50 mM
Hepes, 1% Triton, 2 mrvi EDTA, 2 jiM leupeptin, 2 jiM pepstatin,
1 mM PMSF, 0.1 mg/ml bacitracin, 100 U/ml aprotinin, 1 mM Na
orthovanadate, and 50 mrvi sodium fluoride. The homogenate was
incubated for one hour in the cold, centrifuged at 10,000 g for 10
minutes, then at 100,000 g for one hour. The crude 100,000 g
spleen supernatant was used for receptor binding while the muscle
supernatant was further partially purified by wheat germ aggluti-
nm (WGA) affinity chromatography [21, 22]. In brief, the 100,000
g supernatant was loaded onto prewashed WGA and incubated at
4°C for two hours on a rotator device. Receptors adsorbed to
WGA were washed extensively in the cold and then eluted with
150 mM NaCI, 50 mM HEPES, 0.1% triton X-100 containing 0.45
M N-acetylglucosamine at pH 7.6. Inhibitors were added to this
receptor isolate to give a final concentration of 10 mivi -glycer-
ophosphate, 25 ms NaF, 2 jiM leupeptin and 100 U/ml aprotinin.
These partially purified receptors were used for IGF-I receptor
binding. Solubilized receptor binding was measured by incubating
200 jig of spleen supernatant protein or 3 jig WGA semipurified
muscle receptor protein at 4°C overnight in binding buffer with
125T1GF1 and with or without 10_6 M unlabeled IGF-I or
des(1-3)IGF-I to measure nonspecific binding. The 1251-IGF-I
receptor complex was pelleted by adding 35% PEG (300 jil) and
!-fsu et al: K deficiency 365
Table 1. Serum K, body and organ weight, food intake, and food conversion efficiency
Weight g Food
Group N
Serum K
mEqiliter
BodyBody
day 0
—
Kidney Muscle Spleen Liver
______
Cumulative
food intake
g/8 days
conversion
efficiency
%day 8
Control 7 4.0 0.09 178 3 212 3 0.81 0.02 1.34 0.03 0.65 0.03 7.79 0.51 111 3 30.0 3.0
Low K 7 2.6' 0.13 179 3 189° 3 1.02° 0.03 1.19' 0.01 0.54 0.03 8.30 0.34 112 2 9.0k' 1.0
Control 7 3.9 0.08 179 2 212 3 0.95F 0.01 1.3 0.02 085h 0.04 6.99 0.29 106 2 32 1.1
Treated
Low K 7 2.3 0.07 181 2 189 2 1.20° 0.04 1.22 0.01 0.76c 0.04 8.01 0.30 108 3 8.3 1.4
Treated
Control rats were on a 1% K diet and were pair fed with low K rats on a 0.01% K diet. Treated rats received IGF-I s.c. for 8 days. Food conversion
efficiency = food intake divided by body weight gain.
U Low K vs. Control, P < 0.01
b Control treated vs. Control, P < 0.05
C Low K treated vs. Low K, P < 0.01
0.3% human y-globulin (100 j.tl), washed twice and counted in a
y-eounter. Nonspecific binding values measured with cold IGF-I
or des(1-3)IGF-I were similar.
IGF-I degradation assay
Kidney plasma membranes (100 .tg protein) were incubated at
37°C with I X l01° M '251-IGF-I in KRH pH 7.4 containing 1 mM
monoiodotyrosine and 0.3% BSA. Aliquots were removed after
30 and 60 minutes and an equal volume of 20% cold TCA added.
After 10 minutes at 4°C the samples were centrifuged. The
formation of TCA soluble radioactivity was taken as a measure of
degradation.
Western tigand blot
Samples containing 3 ji.l serum or 200 .tg solubilized muscle
protein were electrophoresed in a 12.5% SDS-polyacrylamide gel
under non-reducing conditions. Separated proteins were electro-
blotted onto nitrocellulose filters (BioRad Semi-Dry Transfer
Cell) and then incubated with a solution containing one million
cpm of '251-IGF-I and 1251-IGF-II overnight at 4°C and visualized
by autoradiography [12, 231. The signal was measured by densi-
tometiy (Gel Scan XL; Pharmacia LKB, Alameda, CA, USA),
though it should be recognized that this is not truly quantitative
because of variations in the transfer of proteins to the nitrocellu-
lose.
Western immunoblot analysis of IGFBP-1
Crude kidney plasma membranes (100 g protein) were elec-
trophoresed in 12.5% SDS-polyacrylamide gels under non-reduc-
ing conditions and electroblotted onto nitrocellulose [12]. Mem-
branes were blocked in Tris-buffered saline with 0.05% Tween-20
containing 3% BSA at 37°C for one to two hours and incubated
with the same buffer containing polyclonal rabbit antihuman-
IGFBP-1 (UB[, Lake Placid, NY, USA) at 4°C overnight. Mem-
branes were then incubated with HRP-linked anti-rabbit-IgG
(Amersham International Plc, Amersham, UK) at room temper-
ature for one hour. The signals were visualized by enhanced
chemiluminescence (ECL; Amersham, Arlington Heights, IL,
USA).
Radloimmunoassay (RIA) of serum, kidney and muscle IGF-I
As described before [17], IGF-I was measured by RIA in
acid-ethanol extracts of serum and acetic acid extracts of kidney
and muscle with a commercial RIA kit (Nichols Institute, San
Juan Capistrano, CA, USA). Recovery of IGF-I added to homog-
enate of kidneys from control and K depleted rats averaged 103
5%, and 97 3%, respectively. Recovery from serum averaged
108 2% and 102 4%, respectively. Corrections for serum
IGF-I contamination of kidney samples were not made since
serum trapped in kidney comprises less than 2% of the organ
volume and the IGF-l in serum accounts for —6% of kidney tissue
IGF-I content [24].
Biochemical measurements
Serum K was determined in a 1L943 flame photometer (Instru-
mentation Labs, Lexington, VA, USA) and tissue protein by the
BioRad method (BioRad Laboratories, Richmond, CA, USA).
Data analysis
Phosphorimager and autoradiographic readings of the mRNAs
of interest were adjusted for the corresponding 18S rRNA read-
ing. The average of the controls was assigned a value of 100 and
all results were expressed in relation to this value. For comparison
between two groups, the data were analyzed with the Student's
unpaired t-test. When four groups were compared an analysis of
variance followed by Scheffe's test was used. A P value <0.05 was
taken as significant. Results are expressed as mean SEM and are
from 6 to 7 rats/group.
RESULTS
Serum potassium levels, body and organ weights and food
conversion efficiency
The results from the four groups of animals studied are listed in
Table 1. At the end of the eight-day study period serum K level
(2.6 0.13 meq/dl), body wt and gastrocnemius muscle weight
were all significantly lower in the vehicle-treated K restricted rats
compared to the controls pair fed a 1% K replete diet. Intake of
food decreased when the rats were placed on the 0.01% K diet
and averaged 14 g/day. This was considerably lower than the
average intake of 20 g/day by rats allowed an ad libitum intake of
a 1% K diet. Food conversion efficiency in the the K depleted rats
was one third that observed in the pair fed controls. Despite equal
food consumption, the K deficient rats gained 10 1.5 g over
eight days compared to 34 3.5 g gained by the controls. In
contrast to the lower body and gastrocnemius muscle weight,
Fig. 1. Relative IGFBP-1, -2, -3, -4, and -5
mRNA levels in kidney (A) and muscle (B)
from pair.fed control (LI) and K deficient ()
rats. K deficient rats were maintained on a
0.01% K diet and controls were pair fed a 1%
K diet for eight days. Messenger RNA levels
were detected by Northern blot analysis and
corrected for the amount of 18S rRNA
transferred. Corrected values are expressed
relative to the average value of the control
group which is assigned a value of 100.
Representative autoradiograms from control
and experimental samples run in the same gel
are shown. Results are mean SEM, 6
rats/group. *p < 0.05; < 0.01.
kidney weight was 26% greater in K depleted rats than in the
controls (1.02 0.03 vs. 0.81 0.02 g, respectively, P < 0.01).
Liver and spleen weights did not differ between the two groups.
The reduced muscle weight could not be accounted for by a
change in water content since after drying to constant weight the
percent dry weight in control and K deficient muscle was similar
(21 0.6 vs. 22 0.4%, respectively).
Treating K deficient rats with IGF-I had no impact on food
intake, food conversion efficiency and body and gastrocnemius
muscle weight compared to the vehicle treated K deficient rats
(Table 1). However, kidney and spleen weight increased signifi-
cantly (P < 0.01). Kidney weight in these IGF-I treated K
deficient animals (1.2 0.04 g) exceeded that of the K deficient
and control vehicle treated rats by 18 and 48%, respectively.
Spleen weight of these IGF-I treated rats exceeded that of
untreated K deficient rats by 41%. To determine whether the
renal response to IGF-I is augmented in the K deficient state, we
treated control rats with IGF-I and compared the growth response
to vehicle treated controls consuming a similar dietary intake.
Treatment with IGF-I did not increase body or gastrocnemius
muscle weight, but kidney and spleen weight increased signifi-
cantly (P < 0.01). The fractional increase in kidney weight, 17%,
was similar to the increase noted in treated K deficient rats. This
indicates that sensitivity to IGF-I is maintained but not increased
in K deficiency.
IGFBP mRNA levels
The relative IGFBP mRNA levels in kidney and muscle from K
deficient and control rats are depicted in Figure 1. In the K
deficient state there were significant increases in kidney IGFBP-1
and IGFBP-4 mRNA levels that on average were 330 and 173% of
the control values. In contrast, the IGFBP-3 mRNA levels were
decreased significantly to 53% of the control values; IGFBP-5
mRNA levels were unchanged. In muscle, we could only detect
the IGFBP-3, -4 and -5 mRNAs by Northern blot analysis. The
relative abundance of muscle IGFBP-3 and -4 mRNA levels in K
deficient animals did not differ significantly from that observed in
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Table 2. Immunoreactive IGF-I concentrations in serum, kidney,
and muscle
Serum
Group N nglml
Kidney Muscle
ng/g tissue
Control 7 829 44 227 19 54 6
Low K 7 792 50 491 61' 20 4
IGF-I peptide levels in serum and tissues
These results are summarized in Table 2. The concentration of
IGF-I in serum of K deficient and pair-fed control rats did not
differ significantly. In contrast, kidney IGF-I concentration in-
creased more than twofold in K deficiency, despite the reduced
IGF-I mRNA level. Total kidney IGF-1 content in the K deficient
and control rats averaged 501 57 and 187 12 ng/kidney,
respectively (P < 0.01). In muscle, the IGF-I level fell by two
thirds in the K deficient rats (P < 0.01).
Fig. 2. Relative insulin-like growth factor-I, IGF-I receptor (IGF-IR) and
growth hormone receptor (GHR) mRNA levels in kidneys (A) and muscle
(B) frompair-fed control (E) and K deficient () rats. IGF-I and IGF-IR
mRNA levels were determined simultaneously in a solution hybridization
ribonuclease protection assay and the GHR mRNA by Northern blot
analysis. These values were corrected for the 18S rRNA levels measured
in the same assays. Corrected values are expressed relative to the average
value of the control group that is assigned a value of 100. Representative
autoradiograms are shown. Results are mean SEM, 5 rats/group. <
0.01.
pair fed controls. However, the IGFBP-5 mRNA abundance was
only 36% of the values seen in controls (P < 0.01).
Insulin-like growth factor-I, IGF-I receptor and GH receptor
mRNA levels
The relative abundance of these mRNAs in kidney and muscle
are depicted in Figure 2. In the K deficient state, there was a
significant decrease in the IGF-I mRNA levels in both kidney and
muscle that reached 52% of the control values (P < 0.01). In
contrast, there were no changes in the levels of the IGF-1 receptor
mRNA in either kidney or muscle. The GH receptor mRNA level
in kidney was also unaffected by K deficiency, but in muscle the
mRNA levels were reduced to 60% of the control value (P <
0.01).
IGF-I receptor binding
Receptor binding measured with kidney plasma membranes,
splenic extract and WGA semipurified skeletal muscle receptors
did not differ between the K deficient and pair fed control rats.
The specific binding of radiolabeled '251-IGF-I to kidney plasma
membranes averaged 8.8 0.42 and 8.5 0,61%/100 jig protein,
respectively. Binding to solubilized splenic receptors averaged
7.0 0.84 versus 7.5 0.3%/200 jig protein and binding to WGA
semipurified skeletal muscle receptor binding averaged 7.5 0.49
and 6.9 1.3%/3 jig protein in the the K deficient rats and control
rats, respectively. These results are consistent with the lack of
change in kidney and muscle IGF-I receptor mRNA levels.
Kidney plasma membrane IGF-I degrading activity
The IGF-1 degrading activity of the crude plasma membrane
preparation was measured to determine whether the increase in
kidney IGF-I levels noted above could be a consequence of
decreased degradation (Fig. 3). In the K deficient group mem-
brane degrading activity was reduced significantly compared to
the controls (16 1.4 and 23 1.9%!100 jig protein/60 mm,
respectively; P < 0.05).
Serum IGF binding proteins
Western ligand blot of serum, as depicted in Figure 4, showed
the typical 40 to 44 kDa triplet, 30 to 34 kDa doublet and 24 kDa
band. In K deficiency the 30 to 34 kDa IGFBPs increased by 49%
over the control values (554 38 vs. 371 31 arbitrary
densitometry units, respectively, P < 0.01). This 30 to 34 kDa
doublet was coincident with the size of circulating IGFBP-l and-2.
In contrast the 40 to 44 kDa IGFBP-3 size triplet and the 24 kDa
IGFBP-4 size band were unchanged.
Kidney plasma membrane associated immunoreactive IGFBP-1
To determine whether the threefold increase in kidney IG-
FBP-1 mRNA level was associated with an increased expression
of the protein, kidney plasma membranes were subjected to
Western immunoblot analysis. This analysis showed a significant
56% increase in immunoreactive IGFBP-1 level (Fig. 5). Densi-
tometry readings were 7.0 0.9 versus 4.5 0.4 arbitrary units in
the K deficient and control groups, respectively (P < 0.05).
ap <0.01
0
IGF-l IGF-IR GI-IR
B
Muscle
JOF-IR
A
200 Kidney
I0
IGF-l
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Time, minutes
Fig. 3. Time course of '251-IGF.I degradation by kidney plasma mem-
branes from control (0) and K deficient (•) rats. Kidney plasma
membranes were incubated with I X 10b0 M 1251-IGF-I at 37°C.
Degradation was measured by solubility in 10% TCA. Results are mean
SEM from 7 rats/group. **P < 0.05.
Muscle IGF binding proteins
Western ligand blot of solubilized muscle revealed a single —32
kDa band which was reduced to near half in the K deficient state
(29 3 vs. 14 1.3 arbitrary units, P < 0.01); this is shown in
Figure 6. The decrease in the —32 kDa moiety most likely reflects
a fall in IGFBP-5 since this is consistent with the fall in IGFBP-5
mRNA level noted earlier. Furthermore, of the three IGFBP
mRNAs detected in muscle only the IGFBP-5 gene expressed a 32
kDa protein [25].
DISCUSSION
In this study we set out to determine whether local alterations
in the IGF-I axis in kidney and muscle could account for the
paradoxical renal hypertrophy and muscle wasting that occurs in
K deficient rats. Over an eight-day study period we noted that
food intake, food utilization, body weight and skeletal muscle
mass declined. In contrast, kidney weight increased and exceeded
that of the pair fed normal control rats by 26%. Administration of
IGF-I to K deficient rats failed to restore body or gastrocnemius
muscle weight, but stimulated further renal growth. Kidney weight
in these treated rats exceeded that of the untreated K deficient
and control rats by 18 and 48%, respectively. The spleen also
responded significantly to IGF-l treatment and increased in
weight by 41% compared to untreated K deficient rats. When
normal rats were treated with IGF-I a similar response was noted.
Compared to vehicle-treated normal control rats with the same
dietary intake, food conversion efficiency and body and gastroc-
nemius weights were unmodified by IGF-I treatment while kidney
and spleen weight increased. Of note, the proportional increase in
kidney weight in controls and K deficient IGF-I treated rats was
comparable, signifying that sensitivity to IGF-I is preserved, but
not increased in K deficiency. This organ selective sensitivity to
IGF-.I has also been described in GH and protein deficient states.
When GH deficient rats are treated with IGF-I body growth is
stimulated, but there is a disproportionate increase in kidney and
spleen size [26]. When protein restricted rats are treated with
IGF-I the kidney and spleen enlarge but body growth remains
stunted [27]. This latter observation raises the likelihood that the
pattern of response to IGF-I supplementation in the K deficient
and pair-fed normal rats may, at least in part, be due to reduced
food intake. Diminished food utilization may also contribute in K
deficiency.
Potassium deficiency also produced changes in the serum and
tissue IGFBP profiles. This is important for the IGFBPs' impact
on IGF-I physiology in several important ways [reviewed in 8]. In
the circulation they limit the immediate bioavailability of IGF-I by
storing it in a slow release form and influence the transport of
IGF-I out of the vascular bed. In the tissues they serve to
modulate the cell-type specific localization of the growth factor.
Hereby regulating the interaction of IGF-I with the IGF-I recep-
tors, IGFBPs may inhibit or even facilitate the activity of the
growth factor. In K deficiency the serum IGFBPs of molecular
weight 30 to 34 kDa, consistent with the size of IGFBP-1 and -2,
were increased by 49%. It can be anticipated that this will lead to
an increase in the proportion of circulating IGF-I bound in low
molecular weight complexes [9]. Since IGF-I complexed to
smaller IGFBPs escape faster out of the circulation than IGF-I
bound in the more abundant 150 kDa IGFBP-3 complex [28],
tissue exposure to IGF-I will likely increase [9, 13, 14]. In kidney
the most prominent change was a threefold increase in IGFBP-1
mRNA levels. This was accompanied by an increase in IGFBP-1
protein associated with the kidney plasma membranes indicating
enhanced protein production. IGFBP-4 mRNA levels also in-
creased but to a lesser extent than IGFBP-1. The levels of
IGFBP-3 mRNA levels fell. The significance of these changes is
unclear since the true function of each of these IGFBPs in kidney
has not been established. However, as discussed later the increase
in cell membrane associated IGFBP-1 may serve to trap the IGF-I
in the kidney. In skeletal muscle we detected the mRNAs of
IGFBP-3, -4 and -5 mRNA by Northern blot analysis. In K
deficiency there was a marked decrease in the IGFBP-5 mRNA
levels. This was accompanied by a decrease in the levels of a —32
kDa IGFBP that is consistent with the size of IGFBP-5 [25]. The
significance of this requires further study since the action of
IGFBP-5 in muscle has not been established. It has been sug-
gested that IGFBP-5 may play a role in myoblast differentiation by
modulating IGF-1 action [29].
Serum IGF-I peptide levels were similar in the K deficient and
pair-fed control rats. In contrast the kidney IGF-I peptide levels
increased by more than twofold in K deficiency and suggests that
IGF-I may play a role in inducing the renal hypertophy in these
rats. Interestingly, the increase in kidney IGF-I peptide occurred
despite a near 50% fall in kidney IGF-I mRNA levels. Several
mechanisms could account for this disparity between gene and
protein expression. First, the delivery of IGF-I to kidney cells may
increase because of the elevated circulating —30 to 34 kDa
IGFBPs that facilitate the movement of IGF-I into tissues [13, 14].
Second, there may be more trapping of circulating and locally
derived IGF-I within the kidney because of the increase in kidney
plasma membrane associated IGFBP-1. Indeed, IGFBP-1 is pro-
duced in the same nephron segments as IGF-I and is thus
strategically located to trap the kidney produced IGF-I, even if
production is reduced [30]. The sequestered IGF-I could then
serve as a storage pooi from which bioavailable IGF-I is released
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Fig. 4. Autoradiogram of Western ligand blot
of serum from pair fed control and K deficient
rats. Serum proteins were separated by
electrophoresis and electroblotted to nitro-
cellulose as described in Figure 5. IGFBPs were
detected by incubation with a mixture of
12511GF1 and '251-IGF-ll.
Fig. 5. Western immunoblot of kidney plasma
membranes with an antibody against IGFBP-1.
Plasma membranes were electrophoresed in
12.5% SDS-polyacrylamide gels under non-
reducing conditions and electroblotted onto
nitrocellulose. Following incubation with anti-
IGFBP-1 antibody the signal was detected by
enhanced chemiluminescence.
Fig. 6. Autoradiogram of Western ligand blot
of gastrocnemius muscle extract from pair fed
controls and K deficient rats.
in a sustained manner. A third mechanism potentially contribut-
ing to the increased kidney IGF-I content is altered renal IGF-I
degrading activity. In K deficient kidneys, plasma membrane
IGF-1 degrading activity was reduced by 30%. Whether this
reflects a true decrease in IGF-I degrading activity or resistance to
IGF-I because of binding of the peptide to IGFBP-1 requires
further study. Finally, though unlikely, enhanced post-transcrip-
tional processing could conceivably lead to increased IGF-I
production even though the mRNA levels are reduced. Our
findings differ in some respects from that of Flyvbjerg et al [7],
who observed a transient increase in kidney IGF-1 content that
returned to baseline after seven days of K restriction. They also
reported that kidney IGF-1 mRNA levels were unchanged and
serum IGF-1 levels were slightly reduced. It is possible that these
differences are related to the age of the animals studied. Flyvhjerg
et al [71 used younger and more rapidly growing rats than those in
the present study.
We considered the possibility that increased IGF-I receptor
binding, in addition to increasing the kidney IGF-1 levels, might
contribute to the exaggerated renal growth in K deficiency. This
was not the case, since the receptor binding did not differ from
control values in the kidney plasma membrane. Similarly, K
deficiency did not modify IGF-I receptor binding in muscle or
spleen.
In muscle of K depleted rats IGF-I mRNA and peptide levels
were low. Since GH receptor mRNA levels were reduced it is
likely that the impaired IGF-I expression is, at least in part, due to
a deficiency in the number of GH receptors. It should be
recognized that we did not measure GH receptor binding and that
gene and protein expression do not necessarily correlate. How-
ever, it has been reported that in K deficient rats GH binding to
receptors in liver plasma membranes is reduced [31]. Taken
together, it is conceivable that a shortage of Gil receptors is a
cause of the resistance to the growth promoting actions of the
hormone described in hypokalemic rats [15]. Tn kidney, in contrast
to muscle, we found no significant change in GH receptor mRNA
levels. Nevertheless, as described above, the IGF-I mRNA levels
were reduced. This suggests that some defect other than a
shortage of GH receptors accounts for the impaired IGF-I gene
expression in kidney.
From this study it is evident that K depletion for a period of
eight days results in reduced food intake and utilization and
impaired muscle and body wt gain, enlargement of the kidney and
tissue distinct changes in local IGF-I systems. In muscle GH
receptor and IGF-I gene expression, IGF-I peptide content and
TGFBP levels were decreased. Together with the reduced food
intake and utilization these changes likely contribute to the
attenuated muscle growth present in these rats. In kidney the
changes were different, The organ was enlarged, the IGF-I
peptide concentration and IGFBP-l gene and protein expression
were increased, and sensitivity to IGF-I was retained. Since IGF-I
gene expression was reduced in the kidney it is improbable that
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the increase in kidney IGF-I peptide level is due to increased
renal production. A more likely explanation is that the increase in
kidney IGF-I is the consequence of a number of factors including
enhanced delivery to the kidney, increased sequestration by
IGFBP-1 and decreased local degradation. Finally, we propose
that this increase in local IGF-1 levels in the IGF-I responsive
kidney after eight days of K deficiency may, in addition to other
factors [32], play a role in the pathogenesis of the renal enlarge-
ment.
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